Researchers converted Duchenne patient stem-cell teratomas into humanized model systems that serve as “living test beds” for gene editing approaches. In these models, both gene-corrected cell transplants and lipid nanoparticle base editing restored dystrophin, with full-length recovery appearing dependent on muscle maturation. The work targets a key translational obstacle in Duchenne—how to assess editing quality and functional protein restoration in a humanized tissue context that captures relevant biology. It also provides a platform for iterating delivery and editing strategies. For the DMD field, the study strengthens the case for tissue-context preclinical evaluation prior to scaling into larger translational programs, while highlighting that editing readouts may vary with maturation state and model design.